This trial is evaluating whether Rocuronium 1.5mg/kg/hr will improve 2 primary outcomes in patients with Prostate Cancer. Measurement will happen over the course of 1 year.
This trial requires 130 total participants across 2 different treatment groups
This trial involves 2 different treatments. Rocuronium 1.5mg/kg/hr is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Symptoms of prostate cancer are usually gradual. Symptoms frequently precede the development of a symptomatic tumour by one to two years. Symptoms usually include an inability to urinate or to pass urine at night. Symptoms may also include weakness and trouble with ejaculation. Some men also have problems with incontinence. Symptoms also may include increased fat in the bones of the back, a lump in the testes or lumps in the neck. Complications of prostate cancer include low libido and impotence. Complications are more likely to occur in men who have had prostate cancer before.
The incidence of PCa in the United States is increasing as previously observed in other developing countries. The age-standardized incidence rates of PCa incidence rates are 3.5-4.0/100,000 population per year for whites, and 4-4.5/100,000 population per year for black and gray and Hispanics. In the next 3-4 decades, it is projected that approximately 2.5 million persons in the United States will develop PCa, including a new population of PCa survivors who are at a higher risk of PCa recurrence.
The 5-year and 10-year disease-specific survival rates were 73% and 66%, respectively, with a median survival of 80+ months. The 5-year and 10-year disease-specific mortality rates were 25% and 24%, respectively. Median survival time was 77+ months. Results from a recent clinical trial, the 10-year disease-specific survival rate was comparable to that described in the literature but shorter than those quoted in studies of other countries. Most treatments are conservative, and the mortality and morbidity are significantly increased in men with high-risk disease, especially with metastatic disease.
Prostate cancer has not been found to be cured, but can be controlled with treatment. Prostate cancer often begins as a slow-growing (stage T1 or T2) or asymptomatic (prostate-specific antigen undetectable disease) prostate tumor. Prostate cancer can be cured if all the cancer is removed. The cure rate depends on the stage of the cancer when treatment is started. For Stage T1 cancer, 80% can be cured with radical prostatectomy; with Stage T2 or T3 disease, 75% to 90% can be cured, and with Stage 4 disease, 25% to 40% can be cured. Prostate cancer is the second deadliest cancer in the U.S.
Patients younger than seventy-five must be aware of the risks of radiation therapy and have an opportunity for counseling regarding the risks and benefits of the therapy.
The most famous cause of prostate cancer is age, and other factors such as gender, race and alcohol intake are known to be inversely associated. Furthermore, it is clear that other environmental risks must be involved as well, but the reason why these other risks are not causative is not clear. Finally, there is some evidence that prostate cancer has a genetic component. Prostate cancer, thus, may be a disease of multiple causes.
Patients with high baseline risk PSA levels, low-volume intermediate- and high-risk disease and high-risk Gleason scores will be interested in joining treatment trials. Patients with favorable-risk disease and low-volume intermediate- and high-risk disease would not be eligible.
We think, that rocuronium 1.5 mg/kg/hr should be used when the patient has an increased response to the stimuli of muscle contraction during surgery, for the avoidance of the occurrence of muscle relaxant.
Rocuronium 1.5 mg/kg/hr in all patients with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) undergoing transrectal ultrasound guided needle-core prostate biopsy resulted in significantly shorter mean biopsy time but no difference in mean duration of anaesthesia, or postoperative analgesic requirements.
Rocuronium 1.5 mg/kg/hr is a safe and reliable way to intubate patients receiving spinal anaesthesia. This technique was similar to that described in this series of two cases, and was not influenced by the body weight or the sex of the patient.
There appears to be no statistically significant age at diagnosis disparity in [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer), at least in the US. Possible factors in these data include the more frequent use of the prostate-specific antigen test in men, a higher frequency of early detection, and different screening schedules with later onset of disease.
The major goals of PC research should include improved therapies (in particular for metastatic PC), reduced chemotherapy-related morbidity in elderly patients, better patient selection for radiation therapy, and reduction of PC mortality.